Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

The functions of, and interactions between, the innate and adaptive immune systems are
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …

Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …

Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …

Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Base editing—the introduction of single-nucleotide variants (SNVs) into DNA or RNA in
living cells—is one of the most recent advances in the field of genome editing. As around …

Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …